A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
Locations
Alexandria Office
Arlington Office
Fairfax Office
Gainesville Office
Loudoun Office
Woodbridge Office
Learn More About This Trial
Other Relevant Trials
PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Principal Investigator
Robert L. Marsh, MDA Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN‑c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer
